ative:
Non-cash
compensation 1,893 569 7,086 8,408
Other selling,
general and
administrative 2,643 2,564 9,919 9,110
Total selling,
general and
administrative 4,536 3,133 17,005 17,518
TOTAL OPERATING EXPENSES 31,027 20,098 95,630 80,691
OPERATING LOSS (30,122) (19,997) (94,581) (80,157)
OTHER INCOME:
Interest and other
income, net 897 1,650 4,555 6,393
NET LOSS BEFORE INCOME
TAXES (29,225) (18,347) (90,026) (73,764)
Income taxes 36 -- 36 --
NET LOSS $(29,261) $(18,347) $(90,062) $(73,764)
NET LOSS PER COMMON SHARE
Basic and diluted $(0.67) $(0.42) $(2.07) $(1.76)
SHARES USED IN COMPUTING
NET LOSS PER COMMON SHARE
Basic and diluted 43,651,587 43,241,090 43,583,950 41,919,741
Balance Sheet Information:
December 31, December 31,
2007 2006*
(unaudited)
Cash, cash equivalents, interest
receivable and investment securities $64,682 $125,610
Total assets 81,061 140,313
Accumulated deficit (278,274) (188,212)
Stockholders' equity 44,422 123,821
* Condensed from audited financial statements.
'/>"/>SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST2.
Keryx Biopharmaceuticals Announces Additions to Management Team3.
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations4.
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results5.
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT6.
Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan7.
Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance8.
Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors9.
Keryx Biopharmaceuticals to Present at Bank of America Investment Conference10.
Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast11.
Genta Announces Senior Management Changes